Post-tamoxifen use of Femara available in Korea

Published: 2004-11-09 06:57:00

Updated: 2004-11-09 06:57:00

Novartis Korea said on November 4 that the Korea Food and Drug Administration has approved an extended adjuvant treatment with Femara (letrozole) in postmenopausal women with early breast cancer who had completed fiver years of therapy with tamoxifen.

Ealier, Novatis Headquarters announced tha...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK